A Phase 3 interventional study of Bosentan in Idiopathic Pulmonary Fibrosis, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
This study's enrollment of 128 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Browse Idiopathic Pulmonary Fibrosis studies →Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
First submitted before Actelion became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients should have completed all the assessments from the BUILD 3 (NCT00391443) end of study (EOS) visit.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For patients who were administered bosentan during BUILD 3 (NCT00391443): Same dose will continue For patients who were administered placebo during BUILD 3 (NCT00391443): Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg
Drug: Bosentan
For patients who were administered Bosentan during BUILD 3 (NCT00391443): continue on same dose For patients who were administered placebo during BUILD 3 (NCT00391443): Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)
Also known as: Tracleer
Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Mean extent of exposure to bosentan treatment in months
Time frame: Start of study to end of study, up to 21 months
Number of Patients Exposed to Bosentan Over Time
Numbers of participants exposed to bosentan treatment over time
Time frame: Start to end of study, up to 21 months
Adverse Events (AE) Leading to Discontinuation of Study Drug.
Number of participants with at least one AE that led to permanent discontinuation of study treatment.
Time frame: Start to end of study, up to 21 months
Treatment-emergent Serious Adverse Events (SAE)
Number of participants with at least one SAE during the study.
Time frame: up to 21 months plus 28 days after the end of study drug
Occurrence of Liver Function Test (LFT: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)) Abnormality.
Number of participants with an increase in ALT and/or AST to \> 3 times upper limit of normal during the study.
Time frame: up to 21 months, plus 24 hours after the end of study treatment
Patients were enrolled at 61 centers in 15 countries (Australia, Belgium, Canada, Czech Republic, France, Germany, Ireland, Israel, Italy, Japan, South Korea, , Spain, Switzerland, UK, and USA. The first patient started on 5 March 2008 and the last patient, last visit was on 01 April 2010.
| Milestone | Bosentan Treatment |
|---|---|
| Started | 128 |
| Completed | 83 |
| Not completed | 45 |
| Withdrew: Death | 18 |
| Withdrew: Adverse event | 14 |
| Withdrew: Withdrew consent | 5 |
| Withdrew: Preparation for lung transplant | 8 |
Mean extent of exposure to bosentan treatment in months
| months | Bosentan Treatment |
|---|---|
| Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | 6.4 ± 4.6 |
Numbers of participants exposed to bosentan treatment over time
| Participants | Bosentan Treatment |
|---|---|
| For at least 4 months | 74 |
| For at least 8 months | 44 |
| For at least 12 months | 17 |
| For at least 16 months | 7 |
| For at least 20 months | 2 |
Number of participants with at least one AE that led to permanent discontinuation of study treatment.
| participants | Bosentan Treatment |
|---|---|
| Adverse Events (AE) Leading to Discontinuation of Study Drug. | 32 |
Number of participants with at least one SAE during the study.
| participants | Bosentan Treatment |
|---|---|
| Treatment-emergent Serious Adverse Events (SAE) | 51 |
Number of participants with an increase in ALT and/or AST to \> 3 times upper limit of normal during the study.
| participants | Bosentan Treatment |
|---|---|
| Occurrence of Liver Function Test (LFT: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)) Abnormality. | 3 |
Collected over Up to 28 days after the end of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bosentan Treatment | — | 51/128 (39.8%) | 5/128 (3.9%) |
| Event | Bosentan Treatment |
|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 23/128 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/128 |
| Lower respiratory tract infectionInfections and infestations | 4/128 |
| PneumoniaInfections and infestations | 4/128 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/128 |
| Lung transplantSurgical and medical procedures | 3/128 |
| Coronary artery diseaseCardiac disorders | 2/128 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/128 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 1/128 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/128 |
| Event | Bosentan Treatment |
|---|---|
| LIVER FUNCTION TEST ABNORMALInvestigations | 2/128 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 1/128 |
| IDIOPATHIC PULMONARY FIBROSISRespiratory, thoracic and mediastinal disorders | 1/128 |
| OEDEMA PERIPHERALGeneral disorders | 1/128 |
| Age, Continuous(years) | Bosentan Treatment |
|---|---|
| Mean | 65.4 ± 8.2 |
| Age, Customized(participants) | Bosentan Treatment |
|---|---|
| 18-40 years | 1 |
| 41-60 years | 33 |
| 61-70 years | 62 |
| >70 years | 32 |
| Sex: Female, Male(Participants) | Bosentan Treatment |
|---|---|
| Female | 31 |
| Male | 97 |
| Region of Enrollment(participants) | Bosentan Treatment |
|---|---|
| Australia | 12 |
| Belgium | 1 |
| Canada | 14 |
| Czech Republic | 1 |
| France | 3 |
| Germany | 11 |
| Ireland | 1 |
| Israel | 4 |
| Italy | 2 |
| Japan | 8 |
| Korea, Republic of | 5 |
| Spain | 8 |
| Switzerland | 4 |
| United Kingdom | 3 |
| United States | 51 |
No study locations are listed for this record.
The record gives a start of Apr 2008, a primary completion of Apr 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan
Idiopathic Pulmonary Fibrosis →